Status:

UNKNOWN

Influence of Clearing Open-capsule Device on Refractive Predictability in Cataract Patients

Lead Sponsor:

Hanita Lenses

Conditions:

Cataract

Eligibility:

All Genders

50-80 years

Phase:

NA

Brief Summary

CleaRing is intended to reduce posterior capsular opacification in cataract patients. The device is intended to be implanted together with standard posterior chamber IOL during cataract surgery.

Detailed Description

Study Design: This study is a prospective, single-group, single-center, open-label study. Each study subject will be implanted with a CleaRing device together with SeeLens AF IOL in a single eye. St...

Eligibility Criteria

Inclusion

  • The subject is between 50 and 80 years of age The subject is designated for cataract surgery
  • Eye designated for the study fulfills the following criteria:
  • Potentially able to achieve a good vision (by the opinion of the investigator)
  • ACD is at least 2.5mm (from epithelium)
  • Corneal astigmatism is at most 2.0 DPT
  • Axial length is between 22.0 and 26.0 mm
  • Able to obtain pupil dilation of at least 6.0 mm
  • Average keratometry values between 42.0 and 46.0 D Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

Exclusion

  • Subject diagnosed with glaucoma of any type or having intraocular pressure above 24mmHg
  • Subject who has undergone previous intraocular surgery in eye designated for the study
  • Subject with a corneal abnormality that would prevent stable and reliable refraction
  • Subject with weak or torn zonules
  • Subject with Pseudoexfoliation syndrome (PEX)
  • Subject with amblyopia
  • Subject with a retinal disease that in the opinion of the principal investigator would prevent stable and reliable refraction or might be worsened due to implantation of the device
  • Subject is diagnosed with active anterior segment intraocular inflammation
  • Subject is obligated to previous participation in another study with any investigational drug or device within the past 30 days
  • Subject is pregnant

Key Trial Info

Start Date :

January 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04838730

Start Date

January 1 2019

End Date

January 1 2023

Last Update

April 9 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wolfson

Holon, Israel